Uveal melanoma is the most common intraocular primary malignancy.
subtenon injections of steroids and intraocular injection of antiangiogenic agents might reduce radiation-induced complications. 7 There is a growing realization that much ocular morbidity after radiotherapy is caused by the persistence of bulky, necrotic tumor.
Estimating the Prognosis for Survival
Despite good local tumor control, about 20-50% of patients die of metastatic disease within 10 years. Metastatic disease almost always involves the liver and is usually fatal within a few months. 8 Factors indicating a poor prognosis include: increased patient age; larger tumor size, both with regards to diameter and thickness; ciliary body involvement; epithelioid cell type; extraocular extension; lymphocytic infiltration; high mitotic rate; and loss of chromosome 3. Metastatic death occurs almost exclusively in patients with a monosomy 3 melanoma, which is almost always fatal. 9 The highly predictive nature of monosomy 3 loss has encouraged more ocular oncologists to offer cytogenetic tumor typing to all patients with uveal melanoma, performing biopsy in patients treated by radiotherapy. 10, 11, [14] [15] [16] 
Impact of Ocular Treatment on Survival
The Collaborative Ocular Melanoma Study (COMS) Group have performed randomized trials investigating the impact of brachytherapy and pre-enucleation radiotherapy on survival in comparison with enucleation alone; however, these studies lacked sufficient statistical power because many patients that were enrolled were likely to have had a non-lethal melanoma. 6, 22 The COMS study on small choroidal melanomas (report No. 4) suffered from the same shortcoming. 23, 24 It would be ideal if further randomized studies could be performed to determine the impact of ocular treatment on survival; however, any future clinical trials investigating the influence of ocular or systemic treatment on survival should take account of tumor lethality determined by genomic tumor type. Robertson has emphasized the difficulties of performing multicenter, randomized studies because of the large numbers of patients required. 18 With genomic tumor typing and improved prognostication it may be possible to achieve sufficient statistical power for such studies with fewer patients.
Genomic tumor typing and improved statistical methods have enhanced our understanding of uveal melanomas and their natural history. 23 There is growing evidence that metastatic spread occurs at a very early stage at least in some tumors so that by the time the patient presents to an ophthalmologist any opportunities for influencing survival might have gone. 8, 25 It seems that in patients with medium-sized and large tumors, the scope of ocular treatment is only to conserve a comfortable eye with as much useful vision as possible. This realization opens the way for less aggressive ocular treatment with reduced ocular morbidity. With small choroidal melanocytic tumors, management is more controversial.
Some advocate observation until growth is documented, in the hope of avoiding unnecessary treatment; others recommend early therapy, when any opportunities for preventing metastatic spread are greatest. It is relevant that monosomy 3 is present in at least 30% of patients with small melanoma.
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Screening for Metastatic Disease
Screening for metastatic disease is also a topic of controversy. This requires six-or twelve-monthly liver function tests and liver imaging;
however, there is no consensus as to whether screening should be recommended to all patients or only those at high risk of metastasis.
Need for Systemic Adjuvant Therapy
With monosomy 3, or class 2, melanomas, the disease is no longer confined to the eye but is systemic and should be approached in that
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